Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic.

Shum K, Solivan A, Parto P, Polin N, Jahangir E.

Ochsner J. 2016 Fall;16(3):217-24.

2.

Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).

Pituskin E, Haykowsky M, McNeely M, Mackey J, Chua N, Paterson I.

BMC Cancer. 2016 Sep 15;16(1):733. doi: 10.1186/s12885-016-2761-8.

3.

Doxorubicin induced heart failure: Phenotype and molecular mechanisms.

Mitry MA, Edwards JG.

Int J Cardiol Heart Vasc. 2016 Mar;10:17-24.

4.

Multifunctional protein: cardiac ankyrin repeat protein.

Zhang N, Xie XJ, Wang JA.

J Zhejiang Univ Sci B. 2016 May;17(5):333-41. doi: 10.1631/jzus.B1500247.

5.

Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95.

Das A, Durrant D, Mitchell C, Dent P, Batra SK, Kukreja RC.

Oncotarget. 2016 Jan 26;7(4):4399-413. doi: 10.18632/oncotarget.6749.

6.

The differential effects of green tea on dose-dependent doxorubicin toxicity.

Mandziuk S, Gieroba R, Korga A, Matysiak W, Jodlowska-Jedrych B, Burdan F, Poleszak E, Kowalczyk M, Grzycka-Kowalczyk L, Korobowicz E, Jozefczyk A, Dudka J.

Food Nutr Res. 2015 Dec 21;59:29754. doi: 10.3402/fnr.v59.29754. eCollection 2015.

7.

Drug-induced mitochondrial dysfunction and cardiotoxicity.

Varga ZV, Ferdinandy P, Liaudet L, Pacher P.

Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18. Review.

PMID:
26386112
8.

Anthracycline treatment and ventricular remodeling in left ventricular assist device patients.

Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM.

Tex Heart Inst J. 2015 Apr 1;42(2):124-30. doi: 10.14503/THIJ-14-4509. eCollection 2015 Apr.

9.

Cardiovascular toxicities from systemic breast cancer therapy.

Guo S, Wong S.

Front Oncol. 2014 Dec 4;4:346. doi: 10.3389/fonc.2014.00346. eCollection 2014. Review.

10.

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Christenson ES, James T, Agrawal V, Park BH.

Clin Biochem. 2015 Mar;48(4-5):223-35. doi: 10.1016/j.clinbiochem.2014.10.013. Epub 2014 Nov 7. Review.

11.

Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.

Stachowiak P, Kornacewicz-Jach Z, Safranow K.

Arch Med Sci. 2014 Oct 27;10(5):1007-18. doi: 10.5114/aoms.2013.34987. Epub 2013 Apr 30.

12.

Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ, Goyal S.

Front Oncol. 2014 Oct 9;4:277. doi: 10.3389/fonc.2014.00277. eCollection 2014. Review.

13.

Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.

Wasielewski M, van Spaendonck-Zwarts KY, Westerink ND, Jongbloed JD, Postma A, Gietema JA, van Tintelen JP, van den Berg MP.

Open Heart. 2014 Jul 18;1(1):e000116. doi: 10.1136/openhrt-2014-000116. eCollection 2014.

14.

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P.

Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93. doi: 10.1093/ehjci/jeu192. No abstract available.

15.

A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.

Chen YW, Huang HS, Shieh YS, Ma KH, Huang SH, Hueng DY, Sytwu HK, Lin GJ.

PLoS One. 2014 Aug 15;9(8):e104703. doi: 10.1371/journal.pone.0104703. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113703.

16.

Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Kupeli S.

World J Cardiol. 2014 Jul 26;6(7):555-61. doi: 10.4330/wjc.v6.i7.555. Review.

17.

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.

Marinko T, Dolenc J, Bilban-Jakopin C.

Radiol Oncol. 2014 Apr 25;48(2):105-12. doi: 10.2478/raon-2013-0040. eCollection 2014 Jun. Review.

18.

Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.

Jordan JH, Thwin SS, Lash TL, Buist DS, Field TS, Haque R, Pawloski PA, Petersen HV, Prout MN, Quinn VP, Yood MU, Silliman RA, Geiger AM.

Breast Cancer Res Treat. 2014 Jul;146(2):401-9. doi: 10.1007/s10549-014-3021-8. Epub 2014 Jun 18.

19.

Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.

Dong Q, Chen L, Lu Q, Sharma S, Li L, Morimoto S, Wang G.

Br J Pharmacol. 2014 Oct;171(19):4440-54. doi: 10.1111/bph.12795. Epub 2014 Aug 14.

20.

Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.

Seif AE, Walker DM, Li Y, Huang YS, Kavcic M, Torp K, Bagatell R, Fisher BT, Aplenc R.

Pediatr Blood Cancer. 2015 Apr;62(4):704-9. doi: 10.1002/pbc.25043. Epub 2014 Mar 26.

Items per page

Supplemental Content

Write to the Help Desk